TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15885612

Group type: EXPERIMENTAL
Intervention: Engineering schemes incorporating vertical deflections (speed humps or cushions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Safety cameras
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other types of engineering schemes
Number of subjects: 0
Study: 11952885

Group type: EXPERIMENTAL
Intervention: Simvastatin (S) 40 mg for 6 weeks, S 80 mg for 6 weeks, S 80 mg for 24 weeks
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Atorvastatin (A) 20 mg for 6 weeks, A 40 mg for 6 weeks, A 80 mg for 24 weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: Atorvastatin (A) 80 mg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Simvastatin (S) 80 mg
Number of subjects: 47
Study: 9606771

Group type: EXPERIMENTAL
Intervention: Low-TENS (1.7 Hz) for 60 min, five days a week for three months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (physiotherapy only)
Number of subjects: 44
Study: 7617812

Group type: EXPERIMENTAL
Intervention: Lithium-TCA treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: TCA-placebo treatment
Number of subjects: 20
Study: 2095133

Group type: EXPERIMENTAL
Intervention: Ibuprofen sugar-coated tablets (Dolo-Dolgit) 600 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ibuprofen film-coated tablets 600 mg (reference preparation)
Number of subjects: 16
Study: 453256

Group type: EXPERIMENTAL
Intervention: Clindamycin-gentamicin
Number of subjects: 200

Group type: COMPARATOR
Intervention: Penicillin-gentamicin
Number of subjects: 200
Study: 31697573

Group type: EXPERIMENTAL
Intervention: Aspartame (0.425 g, 14% of ADI)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Sucralose (0.136 g, 20% of ADI)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: NNS treatment (aspartame and sucralose)
Number of subjects: 17
Study: 31029381

Group type: EXPERIMENTAL
Intervention: 100–300 μm microspheres
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 300–500 μm microspheres
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 100–300 μm followed by 300–500 μm microspheres
Number of subjects: 138

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 138
Study: 28157599

Group type: EXPERIMENTAL
Intervention: One Session Treatment for specific phobias
Number of subjects: 251
Study: 25155700

Group type: EXPERIMENTAL
Intervention: Information about voluntary medical male circumcision (VMMC) and HIV risk
Number of subjects: 1335
Study: 24517053

Group type: EXPERIMENTAL
Intervention: Huzhang Tongfeng Granule + Jinhuang Ointment (acute phase); Yinlian Tongfeng Granule (remission phase)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Diclofenac Sodium Sustained Release Capsule + Jinhuang Ointment (acute phase); Benzbromarone (remission phase)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study: 21768630

Group type: COMPARATOR
Intervention: TKR without synovectomy
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: TKR with synovectomy
Number of subjects: 67
Study: 19505198

Group type: EXPERIMENTAL
Intervention: Zolpidem tartrate extended-release taken in combination with escitalopram
Number of subjects: 379

Group type: COMPARATOR
Intervention: Placebo combined with escitalopram
Number of subjects: 379
Study: 16918596

Group type: EXPERIMENTAL
Intervention: Topical hyaluronic acid (HA) 0.2%
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 14728633

Group type: EXPERIMENTAL
Intervention: Resistance training of knee extensors and flexors three times a week for 12 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Social activities supervised by an occupation therapist
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 21
Study: 11523256

Group type: EXPERIMENTAL
Intervention: Modified Misgav Ladach technique
Number of subjects: 172

Group type: COMPARATOR
Intervention: Misgav Ladach technique
Number of subjects: 172

Group type: COMPARATOR
Intervention: Pfannenstiel technique
Number of subjects: 172
Study: 9760805

Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CYFRA 21.1
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CEA
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: GM-CSF and CYFRA 21.1
Number of subjects: 34
Study: 7836524

Group type: EXPERIMENTAL
Intervention: 62.5 microM ascorbate in HTF medium
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 62.5 microM ascorbate in Ham's F‐10 medium
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (absence of ascorbate) in HTF medium
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (absence of ascorbate) in Ham's F‐10 medium
Number of subjects: 83
Study: 3296734

Group type: EXPERIMENTAL
Intervention: Oral metoclopramide (2 mg/kg/dose)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intravenous metoclopramide (2 mg/kg/dose)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Prochlorperazine (10 mg/dose)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Metoclopramide (oral and intravenous)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: High-dose oral and intravenous metoclopramide
Number of subjects: 29
Study: 28947382

Group type: EXPERIMENTAL
Intervention: Physiotherapy-led exercise program for 12 weeks
Number of subjects: 43
Study: 27935580

Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance treatment
Number of subjects: 2732

Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance treatment in patients aged >74 years
Number of subjects: 2732

Group type: COMPARATOR
Intervention: Observation only patients
Number of subjects: 2732

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 2732
Study: 24726095

Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Raltegravir 800 mg twice daily
Number of subjects: 155

Group type: COMPARATOR
Intervention: Efavirenz 600 mg once daily plus tenofovir and lamivudine
Number of subjects: 155
Study: 23188890

Group type: EXPERIMENTAL
Intervention: Scratch card technology for random allocation concealment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sequentially numbered, opaque, sealed envelopes (SNOSE) system
Number of subjects: 0
Study: 21559998

Group type: EXPERIMENTAL
Intervention: Stent placement prior to scheduled surgery (group 1)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intraoperative colonic lavage (IOCL) (group 2)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Stent placement (group 1)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study: 18807201

Group type: COMPARATOR
Intervention: Medium income
Number of subjects: 188

Group type: COMPARATOR
Intervention: High income
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Smoking adjustment
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Depression adjustment
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Anger symptoms adjustment
Number of subjects: 188
Study: 16557039

Group type: EXPERIMENTAL
Intervention: CD only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BPD only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD plus BPD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study: 12690366

Group type: EXPERIMENTAL
Intervention: Prism adaptation test (PAT) responders (esotropia <= 8 PD at distance and near with four-dot fusion at near)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Nonresponders (exotropia at distance or lack of four-dot fusion at near)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Responders whose angles built with prism
Number of subjects: 65

Group type: COMPARATOR
Intervention: Patients with esotropia <= 8 PD at near with prisms preoperatively
Number of subjects: 65
Study: 10780154

Group type: EXPERIMENTAL
Intervention: Client-centered group psychotherapy (twice a week, approximately 100 sessions)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Clinical standard treatment (control group)
Number of subjects: 43
Study: 8831655

Group type: EXPERIMENTAL
Intervention: 2-week, four-session group intervention
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (n = 71)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Depressed subjects receiving the intervention
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Nondepressed subjects receiving the intervention
Number of subjects: 145
Study: 1306004

Group type: EXPERIMENTAL
Intervention: Heparin-glucuronylglucosaminoglycane combination
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3743977

Group type: EXPERIMENTAL
Intervention: Ponsky‐Gauderer gastrostomy kit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sachs‐Vine gastrostomy kit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional surgically placed gastrostomy
Number of subjects: 0
Study: 29380190

Group type: EXPERIMENTAL
Intervention: Automated closed-loop goal-directed fluid therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Manual fluid administration (control)
Number of subjects: 46
Study: 27399350

Group type: EXPERIMENTAL
Intervention: Nω‐hydroxy‐nor‐L‐arginine (arginase inhibitor)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy age‐matched control subjects (n = 12)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Subjects with type 2 diabetes
Number of subjects: 12
Study: 25006989

Group type: EXPERIMENTAL
Intervention: Polysaccharopeptide from Trametes versicolor (PSP)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 24

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 24
Study: 22649517

Group type: EXPERIMENTAL
Intervention: Genotype score based on weighted risk alleles regarding low serum 25(OH)D levels
Number of subjects: 9528

Group type: EXPERIMENTAL
Intervention: rs6013897 genotypes (CYP24A1)
Number of subjects: 9528
Study: 20397499

Group type: EXPERIMENTAL
Intervention: Zirconia ceramic post with composite core (Group B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glass fiber composite post with composite core (Group C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Titanium post with composite core (Group D)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zirconia ceramic post with composite core (Group B) with TSC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glass FRC post with composite core (Group C) with TSC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zirconia ceramic post with glass-ceramic core (Group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Groups E, F, G, and H (same post-and-core materials as Groups A-D without TSC)
Number of subjects: 0
Study: 18234424

Group type: EXPERIMENTAL
Intervention: G‐CSF (Filgrastim) 5 mcg/kg/day
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: G‐CSF (Filgrastim) 10 mcg/kg/day
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Dose-intensified AC followed by T
Number of subjects: 172
Study: 19258625

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Walking exercise
Number of subjects: 0
Study: 15572993

Group type: EXPERIMENTAL
Intervention: Lumbar stabilisation exercise training (10-week programme)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 41
Study: 11223696

Group type: EXPERIMENTAL
Intervention: alpha(1)‐Adrenoceptor antagonists such as tamsulosin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: alpha(1A)‐adrenoceptor blockade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: alpha(1D) and alpha(1A)‐adrenoceptor blockade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early treatment with alpha-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic treatment with alpha-blockers
Number of subjects: 0
Study: 9137507

Group type: EXPERIMENTAL
Intervention: D‐galactose (1.9 g/kg BW per day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: D‐glucose‐containing electrolyte infusions
Number of subjects: 80
Study: 8195583

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 42
Study: 3300175

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion therapy (CSII)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conventional injection treatment (CIT)
Number of subjects: 65
Study: 31888699

Group type: COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS) administered to the motor cortex (M1) or dorso lateral prefrontal cortex (DLPFC) for 10 sessions over 4 weeks at 2 mA for 20 minutes.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham group receiving no active tDCS treatment.
Number of subjects: 45
Study: 28844214

Group type: EXPERIMENTAL
Intervention: Chamomile ointment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lanoline (placebo)
Number of subjects: 40
Study: 26507452

Group type: EXPERIMENTAL
Intervention: Tunnel technique + Acellular Dermal Matrix (TUN+ADM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Coronally Advanced Flap + Acellular Dermal Matrix (CAF+ADM)
Number of subjects: 20
Study: 23429642

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily for 5 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Boceprevir 800 mg three times daily for 5 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily + Boceprevir 800 mg three times daily for 5 days
Number of subjects: 24
Study: 21864856

Group type: EXPERIMENTAL
Intervention: Overdrive biatrial pacing at a rate of 80 pulses per minute for 5 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group without pacing
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Overdrive biatrial pacing
Number of subjects: 100
Study: 19214886

Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy (CLE)
Number of subjects: 57
Study: 16729287

Group type: EXPERIMENTAL
Intervention: 8 mg MRA/kg body weight
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 15616416

Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg) for 4 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Folic acid and placebo
Number of subjects: 34
Study: 11207873

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective estrogen receptor modulators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Androgen replacement therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9218932

Group type: EXPERIMENTAL
Intervention: Coca-Cola (325 ml) with 100 mg itraconazole
Number of subjects: 8

Group type: COMPARATOR
Intervention: Water (325 ml) with 100 mg itraconazole
Number of subjects: 8
Study: 7963418

Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 3478276

Group type: EXPERIMENTAL
Intervention: Intra-cervical 15-Me PGF2 alpha gel
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intracervical PGE2 gel
Number of subjects: 42

Group type: COMPARATOR
Intervention: Intra-cervical gel alone (placebo)
Number of subjects: 42
Study: 30007113

Group type: EXPERIMENTAL
Intervention: Planned caesarean
Number of subjects: 2305

Group type: COMPARATOR
Intervention: Planned vaginal birth
Number of subjects: 2305
Study: 26657005

Group type: EXPERIMENTAL
Intervention: Price subsidy + health education (PS+HE) group
Number of subjects: 2567

Group type: EXPERIMENTAL
Intervention: Health education (HE) only group
Number of subjects: 2567

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2567

Group type: EXPERIMENTAL
Intervention: Salt sales survey
Number of subjects: 2567
Study: 23878011

Group type: EXPERIMENTAL
Intervention: Intraoperative external head-cooling technique (Group H)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cardiopulmonary bypass (CPB) only (Group C)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Temperature during aortic cross-clamp period
Number of subjects: 50
Study: 22777320

Group type: EXPERIMENTAL
Intervention: MDC group (n=23)
Number of subjects: 78

Group type: COMPARATOR
Intervention: SRCC/PDC group (n=55)
Number of subjects: 78

Group type: COMPARATOR
Intervention: D1 dissection (n=23)
Number of subjects: 78
Study: 19729984

Group type: EXPERIMENTAL
Intervention: Primary open-angle glaucoma (POAG)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Graves' orbitopathy (GO) with ocular hypertension (OHT)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (healthy eyes)
Number of subjects: 116
Study: 17851701

Group type: EXPERIMENTAL
Intervention: Posterolateral lumbar spinal fusion with pedicle screw instrumentation
Number of subjects: 107

Group type: COMPARATOR
Intervention: Posterolateral lumbar spinal fusion without pedicle screw instrumentation
Number of subjects: 107
Study: 16989163

Group type: EXPERIMENTAL
Intervention: Immunotherapy with Hymenoptera venom
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (patients with allergy to other allergens)
Number of subjects: 32
Study: 14748646

Group type: EXPERIMENTAL
Intervention: Inverted question recasts (30 recasts with auxiliary is and 30 with modal will) during twenty 30‐min enrichment sessions over a 2‐month period.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Play sessions without exposure to inverted is and will questions.
Number of subjects: 34
Study: 9799143

Group type: EXPERIMENTAL
Intervention: Blind approach (V group)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Open approach (H group)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150
Study: 8135387

Group type: EXPERIMENTAL
Intervention: etomidate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: fentanyl
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: midazolam
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: propofol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: thiopental
Number of subjects: 60

Group type: COMPARATOR
Intervention: isoflurane
Number of subjects: 60
Study: 2807362

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 20
Study: 4616806

Group type: EXPERIMENTAL
Intervention: Chlormethiazole (500 mg in 10 ml dose)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Nitrazepam (10 mg single dose)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Overall assessment of treatment
Number of subjects: 68
Study: 31419313

Group type: EXPERIMENTAL
Intervention: Standard treatment: 18 months of teriparatide followed by 18 months of denosumab
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cyclic treatment: three separate 12-month cycles of 6 months of teriparatide followed by 6 months of denosumab
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cyclic treatment
Number of subjects: 70
Study: 30583667

Group type: EXPERIMENTAL
Intervention: Consultation based on Health Belief Model (4 weekly sessions)
Number of subjects: 150
Study: 26700457

Group type: COMPARATOR
Intervention: saline (0.9 mL)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: capsaicin (3 mg in 0.2 mL saline with 7% Tween 80)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: morphine (10 mg kg(‐1))
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: butorphanol (10 mg kg(‐1))
Number of subjects: 11
Study: 24844728

Group type: EXPERIMENTAL
Intervention: Directional stimulation
Number of subjects: 13

Group type: COMPARATOR
Intervention: Omnidirectional stimulation
Number of subjects: 13
Study: 22222293

Group type: EXPERIMENTAL
Intervention: Project Focus intervention group
Number of subjects: 0
Study: 20589920

Group type: EXPERIMENTAL
Intervention: Nicotine lozenges
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 40
Study: 18342923

Group type: EXPERIMENTAL
Intervention: fesoterodine 4 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 2
Study: 15685543

Group type: EXPERIMENTAL
Intervention: pegylated-interferon (PEG-IFN) alfa-2a + ribavirin
Number of subjects: 27

Group type: COMPARATOR
Intervention: IFN alfa-2a + ribavirin
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 27
Study: 12786834

Group type: EXPERIMENTAL
Intervention: Topical 2% fusidic acid plus 0.1% betamethasone cream
Number of subjects: 46

Group type: COMPARATOR
Intervention: Topical 2% mupirocin and 0.1% betamethasone cream
Number of subjects: 46
Study: 11198658

Group type: EXPERIMENTAL
Intervention: Mefloquine 25 mg base/kg plus artesunate 4 mg/kg per day for 3 days (MAS3)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Quinine (10 mg salt/kg every 8 h) for 7 days (Q7)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Mefloquine plus artesunate (MAS3)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Quinine (Q7)
Number of subjects: 108
Study: 9384466

Group type: EXPERIMENTAL
Intervention: Ro 48-8684 (0.1-0.3-1 mg and 1-3-10 mg doses)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Midazolam (0.1 mg(‐1) kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ro 48-8684
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ro 48-8684 (10 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ro 48-8684 (doses increasing from 1 to 10 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ro 61-2466 (metabolite of Ro 48-8684)
Number of subjects: 10
Study: 1553112

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Netilmicin
Number of subjects: 34
Study: 3902475

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30067140

Group type: EXPERIMENTAL
Intervention: HemoSep device
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional cell salvage (control)
Number of subjects: 54
Study: 29519953

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 8
Study: 25982391

Group type: EXPERIMENTAL
Intervention: Hop tablets for 12 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo tablets for 12 weeks
Number of subjects: 120